Vinflunina más trastuzumab en cáncer de vejiga Her2 positivo previamente tratado: reporte de un caso

Abstract

Bladder cancer is relatively common. In Mexico, in 2012, there were 3,245 new cases and 1,666 deaths in México. Platinum salt-based chemotherapy regimens are the standard first line treatment for metastatic disease. To date, no standard therapy has been established as second line, with the data being variable and unclear on this issue. Gemcitabine and Paclitaxel have been studied in this setting, with modest response rates. Vinflunine, a third-generation semi-synthetic vinca-alkaloid, appears to be a reasonable option for patients after first-line platinum-containing chemotherapy. Patients with advanced bladder cancer with over-expression of Her2, have a very poor prognosis. Nevertheless, the case is presented of a 54-year-old man with Her2 positive bladder cancer treated with Vinflunine plus Trastuzumab after recurrence with first-line adjuvant chemotherapy with cisplatin, who achieved a complete response and long-term disease control.